Results 211 to 220 of about 451,267 (297)

Inventory management performance of essential medicines in public health facilities of Jimma Zone, Southwest Ethiopia. [PDF]

PLOS Glob Public Health
Bekele A, Boche B, Anagaw YK, Ayenew W, Worku MC, Geremew DT, Minwagaw T, Melkamu E, Woldeyohanins AE, Tefera BB, Duguma M.   +10 more
europepmc   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

When did medicines become essential?

Bulletin of the World Health Organization, 2010
Jeremy A Greene
doaj  

Time to inclusion of selected medicines for priority diseases in National Essential Medicines Lists compared with the WHO Model List. [PDF]

BMJ Glob Health
Hellamand M, Moleman TE, Post AP, Mantel-Teeuwisse AK, Suleman F, van den Ham HA.   +5 more
europepmc   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

The availability of essential medicines in public healthcare facilities in Afghanistan: navigating sociopolitical and geographical challenges. [PDF]

Health Policy Plan
van Gurp M, Alba S, Ammiwala M, Arab SR, Sadaat SM, Hanifi F, Safi S, Ansari N, Campos-Ponce M, Kok MO.   +9 more
europepmc   +1 more source

Somatic mutational landscape in von Hippel–Lindau familial hemangioblastoma

Molecular Oncology, EarlyView.
The causes of central nervous system (CNS) hemangioblastoma in Von Hippel–Lindau (vHL) disease are unclear. We used Whole Exome Sequencing (WES) on familial hemangioblastoma to investigate events that underlie tumor development. Our findings suggest that VHL loss creates a permissive environment for tumor formation, while additional alterations ...
Maja Dembic, Anne Nørremølle, Lilian Bomme Ousager, Lars van Brakel Andersen, Marie Louise Mølgaard Binderup, Mads Thomassen   +5 more
wiley   +1 more source

Prices and Affordability of Essential Medicines in 72 Low-, Middle-, and High-Income Markets.

JAMA Health Forum
Wouters OJ, Denolle C, Wei J, Papanicolas I.   +3 more
europepmc   +1 more source

Trends and disparity in the provision and consumption of essential medicines in China from 2016 to 2021: institutional, regional, and economic variations. [PDF]

Front Public Health
Zhao M, Lin C, Ding S, Han Y, Zhao Y, Gillani AH, Fang Y.   +6 more
europepmc   +1 more source

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Molecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou   +4 more
wiley   +1 more source